Loading...
Loading...
GLPG| Name | Value |
|---|---|
| Revenues | 150.0M |
| Cost of Revenue | 4.3M |
| Gross Profit | 145.7M |
| Operating Expense | 156.4M |
| Operating I/L | -10.7M |
| Other Income/Expense | 29.1M |
| Interest Income | 20.0M |
| Pretax | 18.5M |
| Income Tax Expense | 13.4M |
| Net Income/Loss | 5.1M |
Galapagos NV is an integrated biopharmaceutical company focused on discovering, developing, and commercializing medicines for high unmet medical needs. The company's pipeline includes filgotinib, a JAK1 inhibitor in clinical trials for various conditions such as rheumatoid arthritis, Crohn's disease, and psoriatic arthritis. Additionally, it has products like GLPG1972 for osteoarthritis, Toledo molecules for inflammation, and GLPG4716 and Ziritaxestat for idiopathic pulmonary fibrosis. Galapagos NV generates revenue through collaboration agreements with Gilead Sciences, Inc., AbbVie S.à r.l., and Novartis Pharma AG, as well as through the development and commercialization of its pipeline products.
